MARY MULCAHY MD NPI 1306870837

NPI Details

Mary Mulcahy, MD is a medical oncology internal medicine in Chicago, IL with 32 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Mary Mulcahy, MD NPI is 1306870837. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: UN OF CALIFORNIA, IRVINE, COLLEGE OF MEDICINE
Graduation Year:1993

The provider's business location address is:

675 N SAINT CLAIR ST
GALTER 21-100
CHICAGO, IL
ZIP 60611-975
Phone: (312) 695-0990
Fax: (312) 695-1106

The NPI 1306870837 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, carfilzomib, 1 mg (HCPCS:J9047)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, pemetrexed, not otherwise specified, 10 mg (HCPCS:J9305)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, rituximab, 10 mg (HCPCS:J9312)
• Injection, bortezomib, not otherwise specified, 0.1 mg (HCPCS:J9044)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, octreotide, depot form for intramuscular injection, 1 mg (HCPCS:J2353)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Automated urinalysis test (HCPCS:81003)
• Unclassified drugs (HCPCS:J3490)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Collection of blood sample from implanted device (HCPCS:36591)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0221)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Injection of drug or substance into vein (HCPCS:96374)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Influenza vaccine split virus, preservative free (HCPCS:90662)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)

The enumeration date for this NPI number is 7/10/2006 and was last updated on 7/17/2009.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.